Publications by authors named "B Kinon"
Schizophrenia is a complex syndrome with taxing symptoms and for which treatment challenges remain. Current dopamine Dreceptor-blocking antipsychotics have well-known limitations, including ineffectively treating across all symptom domains and generating common side effects such as motor disturbances, weight gain, and metabolic dysfunction. New approaches are sorely needed to address the continued unmet treatment needs for individuals living with schizophrenia.
View Article and Find Full Text PDFImproving Translational Relevance in Preclinical Psychopharmacology (iTRIPP).
J Psychopharmacol
November 2023
Animal models are important in preclinical psychopharmacology to study mechanisms and potential treatments for psychiatric disorders. A working group of 14 volunteers, comprising an international team of researchers from academia and industry, convened in 2021 to discuss how to improve the translational relevance and interpretation of findings from animal models that are used in preclinical psychopharmacology. The following paper distils the outcomes of the working group's discussions into 10 key considerations for the planning and reporting of behavioural studies in animal models relevant to psychiatric disorders.
View Article and Find Full Text PDFObjective: Complexity and lack of standardization have mostly limited the use of event-related potentials (ERPs) and quantitative EEG (QEEG) biomarkers in drug development to small early phase trials. We present results from a clinical study on healthy volunteers (HV) and patients with schizophrenia (SZ) that assessed test-retest, group differences, variance, and correlation with functional assessments for ERP and QEEG measures collected at clinical and commercial trial sites with standardized instrumentation and methods, and analyzed through an automated data analysis pipeline.
Methods: 81 HV and 80 SZ were tested at one of four study sites.
Article Synopsis
- There is variability in treatment-resistant schizophrenia (TRS), with some individuals never responding to treatment and others becoming resistant after an initial response, suggesting different underlying causes.
- The study aimed to identify sociodemographic and clinical factors related to the early onset of TRS using a retrospective analysis of a cohort from the South London and Maudsley.
- Results indicated a median treatment time to TRS of about 3 years and 8 months, with more severe initial positive symptoms leading to earlier TRS onset, while long-acting injectable antipsychotics were linked to a later onset.
Article Synopsis
- The study aimed to create a predictive tool for treatment-resistant schizophrenia (TRS) using data from mental health services across four London boroughs, analyzing a large diverse group of patients.
- Data from clinical records of 1,515 patients revealed that 17% developed TRS, with the Cox LASSO survival model producing a Harrel's C index of 0.60, indicating a moderate predictive ability.
- Key predictors of TRS included more inpatient days, increased face-to-face clinical contact prior to treatment, minor cognitive issues, and younger age at the first antipsychotic prescription; however, routine data alone may not be enough for accurate prediction.